Morphine/naltrexone

Morphine/naltrexone
Combination of
By mouth
Legal status
Legal status	US: Schedule II;
Identifiers
CAS Number	1131418-84-2;
	(verify)

The

opioid receptor antagonist. It is a schedule II controlled substance, and is intended for long-term pain caused by malignancy or where lower tiers of the pain management ladder have already been exhausted, and where medications such as oxycodone would otherwise have been indicated.^[1]

King Pharmaceuticals temporarily recalled Embeda in 2011, after complaints from the FDA in regard to King Pharmaceuticals omitting information regarding the potentially fatal reaction if crushed and swallowed and also for making unsubstantiated claims regarding Embeda's reduced abuse potential.[3]

References

^ ^a ^b "Embeda- morphine sufate capsule, extended release". DailyMed. 22 January 2010. Retrieved 7 June 2023.
^ "Medication guide" (PDF). www.fda.gov.
^ Eustice C (15 March 2011). "Chronic Pain Drug Embeda Recalled". About.com. Archived from the original on 15 March 2012.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

[Embeda_FDA_label-1] "Embeda- morphine sufate capsule, extended release". DailyMed. 22 January 2010. Retrieved 7 June 2023.

[2] "Medication guide" (PDF). www.fda.gov.

[3] Eustice C (15 March 2011). "Chronic Pain Drug Embeda Recalled". About.com. Archived from the original on 15 March 2012.

[1]